The West Nile virus methyltransferase

西尼罗河病毒甲基转移酶

基本信息

  • 批准号:
    7842651
  • 负责人:
  • 金额:
    $ 18.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-15 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Many members of the genus Flavivirus are significant human pathogens. The 5' end of flavivirus plus- sense RNA genome contains a type 1 cap (m7GpppAmG). We recently found a general mechanism that the flavivirus NS5 methylates the guanine N7 on the cap and ribose 2'-OH on the first transcribed nucleotide. We also found that the N7 methyltransferase (MTase) is essential for flavivirus replication. Understanding the mechanism of cap methylation is critical for development of inhibitors of this enzyme for antiviral intervention. Our long-range goal is to study the molecular mechanisms of flaviviral replication and to develop anti-WNV therapeutics. The objective of this application is to study the molecular mechanism of flavivirus MTase. We will use West Nile Virus (WNV) as a model to accomplish three aims. Aim 1 is to define the "repositioning" mechanism of the WNV RNA cap methylation. Because of the nature that the two N7 and 2'-O methylations are sequential by one MTase, we hypothesize that substrate GpppA-RNA should be "repositioned" to accept the N7 and 2'-O methyl groups from the methyl donor, S-Adenosyl-Methionine (SAM), during the two sequential methylations. We will test the hypothesis by determining why and how the flavivirus MTases catalyze the sequential reactions. Three models including a translocation model, a dissociation-and-reassociation model, and a dimerization model will be examined. The molecular details during the switch of the two methylation events will be defined. Aims 2 and 3 are to determine crystal structures of favivirus MTase in complex with an N7 viral RNA substrate (Aim 2) and with a 2'-O viral RNA substrate (Aim 3). We recently found that flavivirus MTase methylates cap structures with distinct specificities for viral RNA sequences for the N7 and 2'-O methylations, respectively. Under Aims 2 and 3, we will crystallize and solve the structures of the WNV MTase in complex with viral RNA substrates (including both N7 and 2'-O substrates) and analog methyl donor molecule. The co-crystal structure will reveal how the MTase recognizes their RNA substrates during N7 and 2'-O methylations. The proposed research is innovative and significant, because the flavivirus MTase is unique among all known MTases in which one MTase domain catalyzes two distinct N7 and 2'-O methylations in a viral RNA-dependent manner. The studies proposed here are expected to reveal complementary results to define the mechanism of the flavivirus MTase. The proposed work also fits well with the R21 funding mechanism: high risk but with significant outcome if accomplished. The knowledge acquired will significantly advance our understanding of flavivirus cap methylation, and in the long term, will lay the groundwork for designing inhibitors of the flavivirus MTase for antiviral therapy. PUBLIC HEALTH RELEVANCE: Many flaviviruses cause significant human diseases. Among then, dengue, yellow fever, West Nile, Japanese encephalitis, and tick-borne encephalitis are categorized as the NIAID Priority Pathogens. No effective antiviral therapy is currently available for treatment of flavivirus infections. We recently found that flavivirus methyltransferase (MTase) is a novel target for antiviral therapy. The current proposal is to define the molecular mechanism and function of the flavivirus MTase. These studies are expected to provide critical information for development of MTase therapies and vaccines against flaviviruses.
描述(由申请人提供):黄病毒属的许多成员是重要的人类病原体。黄病毒正义RNA基因组的5'端含有1型帽(m7 GpppAmG)。我们最近发现了黄病毒NS 5甲基化帽上的鸟嘌呤N7和第一个转录核苷酸上的核糖2 '-OH的一般机制。我们还发现,N7甲基转移酶(MTase)是黄病毒复制所必需的。了解帽甲基化的机制对于开发这种酶的抑制剂用于抗病毒干预至关重要。我们的长期目标是研究黄病毒复制的分子机制,并开发抗西尼罗河病毒的治疗方法。本研究的目的是研究黄病毒MTase的分子机制。我们将使用西尼罗河病毒(WNV)作为一个模型,以实现三个目标。目的1是明确西尼罗河病毒RNA帽甲基化的“重新定位”机制。由于两个N7和2 '-O甲基化是由一个MTase连续的性质,我们假设在两个连续的甲基化过程中,底物GpppA-RNA应该被“重新定位”以接受来自甲基供体S-腺苷-甲硫氨酸(SAM)的N7和2'-O甲基。我们将通过确定黄病毒MT酶催化顺序反应的原因和方式来检验这一假设。三个模型,包括易位模型,解离和再结合模型,和二聚体模型将被检查。将定义两个甲基化事件转换期间的分子细节。目的2和3是确定与N7病毒RNA底物(目的2)和与2 '-O病毒RNA底物(目的3)复合的黄病毒MTase的晶体结构。我们最近发现,黄病毒MTase甲基化帽结构,分别对N7和2 '-O甲基化的病毒RNA序列具有不同的特异性。在目标2和3下,我们将结晶并解析与病毒RNA底物(包括N7和2 '-O底物)和类似物甲基供体分子复合的WNV MTase的结构。共晶体结构将揭示MTase如何在N7和2 '-O甲基化期间识别其RNA底物。这项研究具有创新性和重要意义,因为黄病毒MTase在所有已知的MTase中是独一无二的,其中一个MTase结构域以病毒RNA依赖的方式催化两种不同的N7和2 '-O甲基化。这里提出的研究预计将揭示互补的结果,以确定黄病毒MTase的机制。拟议的工作也非常符合R21供资机制:风险高,但如果完成,将取得重大成果。所获得的知识将大大提高我们对黄病毒帽甲基化的理解,从长远来看,将为设计黄病毒MTase抑制剂用于抗病毒治疗奠定基础。公共卫生相关性:许多黄病毒引起重大人类疾病。其中,登革热、黄热病、西尼罗河病毒、日本脑炎和蜱传脑炎被归类为NIAID优先病原体。目前没有有效的抗病毒疗法可用于治疗黄病毒感染。我们最近发现,黄病毒甲基转移酶(MTase)是一个新的抗病毒治疗的目标。目前的建议是确定黄病毒MTase的分子机制和功能。这些研究有望为MTase治疗和黄病毒疫苗的开发提供关键信息。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Flavivirus RNA cap methyltransferase: structure, function, and inhibition.
  • DOI:
    10.1007/s11515-010-0660-y
  • 发表时间:
    2010-08-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Inexpensive electronics and software for photon statistics and correlation spectroscopy.
  • DOI:
    10.1119/1.4869188
  • 发表时间:
    2014-07
  • 期刊:
  • 影响因子:
    0.9
  • 作者:
    Gamari BD;Zhang D;Buckman RE;Milas P;Denker JS;Chen H;Li H;Goldner LS
  • 通讯作者:
    Goldner LS
Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs.
  • DOI:
    10.1016/j.antiviral.2012.12.012
  • 发表时间:
    2013-03
  • 期刊:
  • 影响因子:
    7.6
  • 作者:
    Chen, Hui;Liu, Lihui;Jones, Susan A.;Banavali, Nilesh;Kass, Jorden;Li, Zhong;Zhang, Jing;Kramer, Laura D.;Ghosh, Arun K.;Li, Hongmin
  • 通讯作者:
    Li, Hongmin
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HONGMIN LI其他文献

HONGMIN LI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HONGMIN LI', 18)}}的其他基金

Development of Inhibitors Targeting Flavivirus Methyltransferase
黄病毒甲基转移酶抑制剂的开发
  • 批准号:
    10636605
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries
通过重新利用药物库发现隐球菌病的治疗方法
  • 批准号:
    10308245
  • 财政年份:
    2019
  • 资助金额:
    $ 18.56万
  • 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
  • 批准号:
    10319642
  • 财政年份:
    2018
  • 资助金额:
    $ 18.56万
  • 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
  • 批准号:
    10376239
  • 财政年份:
    2018
  • 资助金额:
    $ 18.56万
  • 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
  • 批准号:
    10318299
  • 财政年份:
    2018
  • 资助金额:
    $ 18.56万
  • 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
  • 批准号:
    10382470
  • 财政年份:
    2018
  • 资助金额:
    $ 18.56万
  • 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
  • 批准号:
    9538444
  • 财政年份:
    2017
  • 资助金额:
    $ 18.56万
  • 项目类别:
New Use of Old Drugs for Zika Virus
老药新用途对抗寨卡病毒
  • 批准号:
    9412543
  • 财政年份:
    2017
  • 资助金额:
    $ 18.56万
  • 项目类别:
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
  • 批准号:
    9053450
  • 财政年份:
    2015
  • 资助金额:
    $ 18.56万
  • 项目类别:
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
  • 批准号:
    8821943
  • 财政年份:
    2015
  • 资助金额:
    $ 18.56万
  • 项目类别:

相似海外基金

Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
  • 批准号:
    10682185
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    475843
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    474485
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10683329
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10481430
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
  • 批准号:
    nhmrc : 1196520
  • 财政年份:
    2021
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10260234
  • 财政年份:
    2021
  • 资助金额:
    $ 18.56万
  • 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10548114
  • 财政年份:
    2021
  • 资助金额:
    $ 18.56万
  • 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
  • 批准号:
    10400318
  • 财政年份:
    2020
  • 资助金额:
    $ 18.56万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
  • 批准号:
    449805
  • 财政年份:
    2020
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了